New insider activity at AIM ImmunoTech ( (AIM) ) has taken place on March 5, 2025.
CEO & President Thomas Equels has made a significant investment in AIM ImmunoTech by purchasing 83,334 shares of the company’s stock, valued at $10,000. This move reflects a strong vote of confidence in the company’s future prospects.
Recent Updates on AIM stock
AIM ImmunoTech has recently announced the appointment of David I. Chemerow to its Board of Directors, bringing extensive experience in finance and operations, which is expected to enhance the company’s strategic direction. Additionally, the company has amended its bylaws to reduce the quorum for stockholder meetings. In other developments, AIM ImmunoTech has decided not to proceed with an offering pursuant to its Registration Statement until after filing its Annual Report for the fiscal year ended December 31, 2024. These strategic decisions and governance changes are likely influencing the market’s perception of AIM’s stock, although specific price target changes were not detailed in the articles.
More about AIM ImmunoTech
YTD Price Performance: -38.64%
Average Trading Volume: 1,034,968
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.28M